Accelerating vaccine research for COVID-19 with high-performance computing and artificial intelligence

on the May 14, 2020


  • HPE is powering research to accelerate discovery of antibodies, antiviral agents and drug candidates to be tested for vaccine development.

  • U.S. DOE's Argonne National Laboratory, Lawrence Livermore National Laboratory and GENCI dedicate HPC and AI technologies to improve speed and accuracy of molecular dynamics simulations.
(More information)


Published on July 8, 2020